Trial record 1 of 1878 for:    PC trial
Previous Study | Return to List | Next Study

PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2009 by Foundation for Cardiovascular Research, Zurich.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
AGA Medical Corporation
Information provided by:
Foundation for Cardiovascular Research, Zurich
ClinicalTrials.gov Identifier:
NCT00166257
First received: September 9, 2005
Last updated: May 26, 2009
Last verified: May 2009

September 9, 2005
May 26, 2009
February 2000
February 2011   (final data collection date for primary outcome measure)
  • Time to death (Fatal stroke, cardiovascular, non-CV), [ Time Frame: continuosly ] [ Designated as safety issue: Yes ]
  • non-fatal cerebrovascular event, [ Time Frame: continuosly ] [ Designated as safety issue: Yes ]
  • peripheral embolism [ Time Frame: continuosly ] [ Designated as safety issue: Yes ]
  • Time to death (Fatal stroke, cardiovascular, non-CV),
  • non-fatal cerebrovascular event,
  • peripheral embolism
Complete list of historical versions of study NCT00166257 on ClinicalTrials.gov Archive Site
  • New arrhythmias, [ Time Frame: continuosly ] [ Designated as safety issue: Yes ]
  • myocardial infarction [ Time Frame: continuosly ] [ Designated as safety issue: Yes ]
  • rehospitalization related to PFO or its treatment [ Time Frame: continuosly ] [ Designated as safety issue: Yes ]
  • device problems [ Time Frame: continuosly ] [ Designated as safety issue: Yes ]
  • bleeding complications [ Time Frame: continuosly ] [ Designated as safety issue: Yes ]
  • New arrhythmias,
  • myocardial infarction
  • rehospitalization related to PFO or its treatment
  • device problems
  • bleeding complications
Not Provided
Not Provided
 
PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism
Randomized Clinical Trial Comparing the Efficacy of Percutaneous Closure of Patent Foramen Ovale (PFO) With Medical Treatment in Patients With Cryptogenic Embolism

The purpose of this study is to compare two treatments strategies to prevent further attacks in patients who have suffered an stroke or occlusion of a major artery with no obvious reason other than a persistent small opening between the upper heart chambers

In patients who have suffered a stroke or occlusion of a large artery in another body part of unknown origin a possible cause is a small opening between the upper heart chambers (patent foramen ovale, it is called). After birth this opening closes in 75% of the population, while it persists in 25% of people. It may allow a small blood clot to pass from the veins of the legs through the heart into the brain or other parts of the body. In order to reduce the risk for a further attack we have today more therapeutic options to choose from but it is unclear which strategy have the best outcome. This study is created to compare the effect of two treatment strategies:

  1. Medical treatment The purpose of medical treatment is to dilute the blood to a degree, that no thrombus formation occurs. Since the opening in the heart persists, treatment is usually recommended lifelong. And patients treated with coumadin must undergo regular blood tests to ensure an adequate effect of the drug.
  2. Catheter closure of patent foramen ovale An alternative method developed to close the small opening in the heart utilizes catheters which are introduced in a blood vessel in the groin and from there advanced to the heart. An umbrella device is then delivered through the catheter, positioned within the small defect and released. The umbrella is overgrown with own tissue within weeks to months and closes the small defect for ever.
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Embolism, Paradoxical
  • Heart Septal Defects, Atrial
  • Device: Percutaneous closure of patent foramen ovale
    Percutaneous implantation of an AMPLATZER® PFO Occluder
  • Drug: Medical antitrhombotic treatment
    Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d
  • Active Comparator: Medical antitrhombotic treatment
    Intervention: Drug: Medical antitrhombotic treatment
  • Experimental: Device Implant
    Percutaneous closure of patent foramen ovale
    Intervention: Device: Percutaneous closure of patent foramen ovale

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
414
May 2011
February 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age below 60 years
  • Ischemic stroke or peripheral thromboembolism, radiologically verified
  • Absence of an identifiable cause of embolism
  • Echocardiographically verified patent foramen ovale
  • Sufficient recovery from index event to allow independent daily activities

Exclusion Criteria:

  • Any identifiable cause for thromboembolic event other than PFO
  • Cardiac diseases: mural thrombus, dilated cardiomyopathy, prosthetic heart valve or mitral stenosis, endocarditis, atrial fibrillation
  • Vascular system: significant atherosclerosis or dissection of the aorta, collagen vascular disease, arteritis, vasculitis
  • Pre-existing neurologic disorders or intracranial disease, e.g., multiple sclerosis, arteriovenous malformations, previous hemorrhage
  • Contraindications for antithrombotic or anticoagulant therapy
  • Patients already on chronic anticoagulant therapy for another disease
  • Previous surgical or percutaneous PFO-closure
  • Drug or alcohol abuse
  • Pregnancy
  • Septicemia or severe infectious disease
  • Severe CNS disease
  • No informed consent
  • Foreseen difficulties with study compliance, especially the long-term follow-up
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Austria,   Belgium,   Switzerland
 
NCT00166257
ICN98008
Yes
Meier, Bernhard, MD, Professor of Cardiology,, University of Berne, Switzerland
Foundation for Cardiovascular Research, Zurich
AGA Medical Corporation
Study Chair: Bernhard Meier, MD Dept. Cardiology, University Hospital Insel, Berne, Switzerland
Foundation for Cardiovascular Research, Zurich
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP